Antibodies in Myeloma: Practical Applications for Nurses

The FDA has granted priority review to odronextamab for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

Patients who received pomalidomide, bortezomib, and dexamethasone achieved a median overall survival of 35.6 months compared with 31.6 months among patients treated with bortezomib and dexamethasone.

In this episode of The Vitals, Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses the treatment journey of a patient who required multiple lines of therapy for ALL.

The FDA has approved bosutinib to treat pediatric patients with Philadelphia chromosome–positive, chronic-phase chronic myelogenous leukemia.

Data suggest that frontline treatment brentuximab vedotin elicits superior outcomes in patients with Hodgkin Lymphoma, regardless of PET2 results.